System N transporters belong to the SLC38 family of sodium-dependent neutral amino acid carriers. What makes them distinctive is their coupling mechanism: they move substrates such as glutamine, asparagine and histidine in either direction across the membrane, coupled to sodium symport and proton antiport. In practical terms, the direction of transport depends on the sodium gradient, the pH environment and the relative availability of amino acids inside and outside the cell. This bidirectionality is not a biochemical curiosity. It means that the same transporter can feed a tumor in one context and drain it in another, which is precisely why these carriers have been so hard to pin down functionally. Historically, they have attracted far less attention than celebrity cancer transporters such as ASCT2 (SLC1A5), LAT1 (SLC7A5) or xCT (SLC7A11), but the accumulating evidence now suggests they deserve a place at the metabolic table.

SLC38A3, also known as SNAT3, is the most ambivalent of the three. In healthy physiology it is a workhorse: it supports the glutamate-glutamine cycle in the brain, contributes to nitrogen detoxification in the liver and is dramatically upregulated in the kidney during metabolic acidosis, where it imports glutamine from the circulation to fuel ammoniagenesis and restore acid-base balance. Its importance is underscored by genetics. Loss-of-function mutations in mice are lethal early in development, and in humans, pathogenic biallelic variants cause developmental and epileptic encephalopathy, with affected children showing global developmental delay, intellectual disability, hypotonia and seizures. Metabolomic analyses of these patients reveal perturbations in glutamate, histidine and nitrogen metabolism, confirming that disrupted glutamine homeostasis is a central disease mechanism.

In cancer, however, SLC38A3 plays a double game. In triple-negative breast cancer, it promotes tumor growth and metastasis in vivo by maintaining intracellular amino acid pools, supporting glutathione production and inhibiting GSK3β, which activates β-catenin signaling and drives epithelial-mesenchymal transition. In non-small cell lung cancer, the transporter mediates the efflux of glutamine and histidine, which paradoxically activates PDK1 and downstream AKT signaling, promoting metastasis. In colorectal cancer, silencing SLC38A3 reduces proliferation and migration, possibly through regulation of the chaperone Hsp70. Yet in esophageal squamous cell carcinoma, SLC38A3 is frequently lost and its suppression correlates with lymph-node metastasis and poor survival, suggesting it can act as an EMT suppressor by physically linking to SETDB1 and impairing SNAIL transcription. In lung adenocarcinoma, some multi-omics analyses even propose a tumor-suppressive role, although the authors caution that this rests mainly on associations rather than functional transport data. The lesson, the Parma team argues, is that SLC38A3 expression alone cannot predict its pro-tumor or tumor-suppressive impact; the functional outcome emerges from the specific metabolic and lineage-dependent programs active within each cancer type.

SLC38A5, or SNAT5, is a different story altogether. It is overexpressed across all major subtypes of breast cancer, with the highest levels in triple-negative patient-derived xenografts, and its expression correlates with poor survival, reduced cisplatin sensitivity and increased proliferation. In pancreatic ductal adenocarcinoma, it is associated with higher tumor grade, poor prognosis and gemcitabine resistance. In colorectal cancer, it is induced by KRAS activation, ETV4 and Wnt/β-catenin signaling, and promotes proliferation, migration, invasion and resistance to oxaliplatin, 5-fluorouracil and irinotecan. In osteosarcoma, it fuels glutamine uptake that sustains glutathione synthesis and activates the PI3K/AKT/mTOR pathway, preventing reactive oxygen species accumulation. Mechanistically, SLC38A5 is a metabolic Swiss Army knife: it imports glutamine, asparagine, serine and glycine, all of which support anaplerosis, lipid biosynthesis and the one-carbon cycle for nucleotide synthesis. Its sodium/proton exchange activity exports protons during amino acid uptake, contributing to intracellular alkalinization and extracellular acidification, which promotes cytoskeletal remodeling and macropinocytosis, enabling cancer cells to scavenge extracellular proteins as an additional nutrient source.

Perhaps the most striking recent finding is SLC38A5’s role in ferroptosis resistance. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation, and cancer cells go to great lengths to avoid it. SLC38A5-mediated glutamine uptake sustains glutathione synthesis, which is required for the activity of GPX4, the key enzyme that prevents lipid peroxidation. In triple-negative breast cancer, the transporter also imports selenium-containing methionine, which activates NRF2 and induces SLC7A11 expression, further reinforcing the antioxidant armamentarium. In colorectal cancer, SLC38A5 facilitates the nuclear translocation of YAP, a co-activator of NRF2, inducing antioxidant genes such as SLC7A11 and GPX4. This means that tumors with high SLC38A5 expression are not only metabolically flexible but also chemically armored against one of the most promising emerging cell death pathways in oncology.

But SLC38A5 does not confine itself to cancer cells. It is also expressed in stromal, immune and endothelial cells within the tumor microenvironment, where it mediates amino acid exchange between malignant and non-malignant populations. In B-cell precursor acute lymphoblastic leukemia, leukemic blasts secrete glutamine, which is taken up by bone marrow mesenchymal stromal cells and converted into asparagine, which is then exported through SLC38A5 and provided back to the leukemia cells. This mechanism protects the blasts against asparagine depletion during treatment with L-asparaginase, one of the mainstays of B-ALL chemotherapy, and is prevented if SLC38A5 is silenced or pharmacologically inhibited. A similar metabolic trade-off occurs in multiple myeloma, where malignant plasma cells release glutamate via SLC7A11, stromal cells internalize it through SLC1A1 and convert it into glutamine, which is subsequently secreted through SLC38A5 to sustain neoplastic growth. In clear cell renal cell carcinoma, SLC38A5 is more expressed in cancer-associated fibroblasts than in normal fibroblasts and sustains their pro-tumoral activity, with silencing lowering the secretion of the chemokine CCL5. This dual cancer-stroma activity positions SLC38A5 as a central metabolic hub of the tumor ecosystem.

SLC38A7, or SNAT7, is the least understood of the three but is rapidly gaining relevance. Unlike its plasma membrane siblings, SLC38A7 is predominantly localized on lysosomal membranes in cancer cells, where it exports proteolysis-derived glutamine and asparagine into the cytosol. Through this activity, it acts as a metabolic gatekeeper linking lysosomal nutrient recycling, derived mainly from internalized extracellular proteins, to mTORC1 activation, supporting cell growth under nutrient limitation. The most direct pro-tumor functional data come from pancreatic cancer, where KRAS-driven MIA PaCa-2 cells maintain proliferation under glutamine restriction by internalizing albumin via macropinocytosis, degrading it in lysosomes and exporting the resulting amino acids through SLC38A7. This pathway activates mTORC1 through a Rag-independent mechanism. In gastric cancer, SLC38A7 is associated with poor prognosis and promotes proliferation, migration, invasion and mitochondrial function, with its expression and pro-tumor effects promoted by METTL3-dependent N6-methyladenosine modification and IGF2BP2-mediated stabilization of its transcript. It also interacts with myosin heavy chain 9, facilitating GSK3β ubiquitination and degradation and thereby activating Wnt/β-catenin signaling. Evidence in lung squamous cell carcinoma, lung adenocarcinoma, cervical cancer and ER-positive breast cancer is growing, although functional validation of transport activity remains limited in many of these contexts.

When it comes to therapeutic targeting, SLC38A5 currently offers the most concrete opportunities. GluγHA, L-glutamic acid γ-monohydroxamate, is the only known direct competitive inhibitor of SLC38A5-mediated glutamine and asparagine influx and efflux, although it is endowed with low affinity, with an IC50 of approximately 0.6 millimolar. Indirect inhibitors include amiloride and the antihelminthic drug niclosamide, which interfere with the sodium/proton exchanger NHE-1, and melatonin, which downregulates SLC38A5 expression. Notably, in triple-negative breast cancer and colorectal cancer, SLC38A5 upregulation is associated with SLC7A11 overexpression, which would counteract ferroptosis but may render cells vulnerable to disulfidptosis, another regulated cell death pathway recently described in other cancer models. Under glucose starvation, reduced availability of NADPH prevents the reduction of SLC7A11-imported cystine, leading to disulfide stress through aberrant disulfide bond formation in cytoskeleton proteins, ultimately causing F-actin collapse and cell death. This suggests that SLC38A5 inhibition may simultaneously damage tumor-intrinsic metabolism and disarticulate microenvironmental nutrient support, pointing to the transporter as a tractable metabolic vulnerability.

In contrast, SLC38A3 and SLC38A7 remain pharmacologically undrugged. For SLC38A3, its context-dependent oncogenic versus tumor-suppressive roles complicate therapeutic inhibition, and its essential physiological roles in the brain, kidney and liver indicate that systemic inhibition may carry significant on-target toxicity. Tumor-selective delivery, perhaps through an Enhanced Permeability and Retention approach based on nanodrugs, coupled with careful pharmacodynamic monitoring, would be required. A database-guided docking analysis identified periodate-oxidized adenosine as a putative computational hit for SLC38A3, but this remains an in silico lead without biochemical binding or transport-inhibition data. SLC38A7 similarly lacks direct inhibitors, and its pharmacological targeting remains conceptual. Potential indirect strategies include targeting the METTL3-IGF2BP2 regulatory axis, the SLC38A7-MYH9 interaction, downstream Wnt/β-catenin signaling or glutaminase activity, but these represent pathway-level interventions rather than selective inhibition of the transporter itself. Moreover, compensatory increases in glycolysis may limit the efficacy of lysosome- and glutamine-targeted combinations.

The Parma researchers also raise an important methodological caveat. Standard cell-culture media differ markedly from human plasma, containing supraphysiological concentrations of several metabolites while lacking others that are present in vivo. Such discrepancies can profoundly bias the evaluation of metabolic dependencies, including amino acid transport and utilization. Supraphysiological concentrations of glutamine in conventional media may artificially increase cell dependence compared with physiological conditions, while the absence of glutamate and asparagine in several media forces their secretion in standard culture. These variations can affect the development of nutritional stress and the resulting cellular responses, meaning that functional assays capable of measuring amino acid flux, transport directionality and metabolic state under real-life conditions will be essential to determine the effective function of each transporter.

Beyond metabolism, System N transporters also exert regulatory functions that expand their impact on tumor biology. SLC38A3 may modulate transcriptional programs through SETDB1-SNAIL-associated mechanisms. SLC38A7 influences β-catenin signaling via MYH9. SLC38A5 affects antioxidant and ferroptosis pathways through the YAP-NRF2 axis. These emerging non-canonical roles, which are not directly linked to transport activity, suggest that System N transporters act not only as nutrient carriers but also as integrated metabolic-signaling nodes. Among the three, SLC38A5 stands out for its microenvironmental reach and finely tuned regulatory mechanisms, differently from SLC38A3 and SLC38A7, whose functions remain largely confined to cancer cells.

Future progress will be required to define how System N transporters integrate metabolic fluxes, macropinocytosis, ferroptosis sensitivity and signaling networks across tumor types. To date, most studies on SLC38A3 and SLC38A7 rely on in silico analyses or in vitro evaluation of mRNA and protein levels, with limited or absent functional validation of transport activity. In the case of SLC38A5, the number of studies has increased substantially in recent years and now includes more functional evidence, partly facilitated by the availability of inhibitors. Given their context-dependent roles, biomarker-guided stratification will be necessary to identify tumors in which these transporters represent dominant metabolic drivers, cooperative nodes or dispensable components. Such integrated approaches will be pivotal to uncover metabolic vulnerabilities and to design precision therapeutic strategies that disrupt the nutrient flow and regulatory networks existing between malignant and stromal compartments. For now, the message is clear: three overlooked transporters are stepping out of the shadow of their more famous SLC cousins, and the pharmaceutical industry may soon have three new metabolic targets to chase.

Subject of Research: System N amino acid transporters SLC38A3, SLC38A5 and SLC38A7 as emerging anti-cancer therapeutic targets

Article Title: The amino acid transporters SLC38A3–SLC38A5–SLC38A7 as novel anti-cancer therapeutic targets

Article References: Madenis, N. E., Chiu, M., Bianchi, M. G., Ughini, C., Castellucchio, M. E., Bussolati, O., & Taurino, G. (2026). The amino acid transporters SLC38A3–SLC38A5–SLC38A7 as novel anti-cancer therapeutic targets. Frontiers in Molecular Biosciences, 13, Article 1959729. https://doi.org/10.3389/fmolb.2026.1959729

Image Credits: AI Generated

DOI: 10.3389/fmolb.2026.1959729

Keywords: SLC38A3, SLC38A5, SLC38A7, System N transporters, amino acid transporters, cancer metabolism, glutamine, asparagine, ferroptosis, macropinocytosis, tumor microenvironment, mTORC1